On Nov. 8, Barr Pharmaceuticals (NYSE:BRL) released third-quarter earnings for the period ended Sept. 30.
- Revenues for Q1 increased 7.1% to $332.4 million.
- Contraceptive products, both generic and proprietary, continued to be drivers of sales growth for the company.
- Operating and net margins declined considerably compared to last year, contributing to a significant decline in EPS.
- The company is acquiring Pliva, and by doing so it will become the world's third-largest generic drug company, after Novartis (NYSE:NVS) and TevaPharmaceuticals (NASDAQ:TEVA).
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q3 2006 |
Q3 2005 |
Change | |
|---|---|---|---|
|
Sales |
$332.4 |
$310.4 |
7.1% |
|
Net Profit |
$52.8 |
$83.2 |
(36.6%) |
|
EPS |
$0.49 |
$0.78 |
(37.2%) |
|
Diluted Shares |
108.1 |
106.3 |
1.7% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q3 2006 |
Q3 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
75.4% |
74.2% |
1.2 |
|
Operating Margin |
34.1% |
40.8% |
(6.8) |
|
Net Margin |
15.9% |
26.8% |
(10.9) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Cash + Invest. |
$767.4 |
$763.6 |
0.5% |
|
Accounts Rec. |
$184.7 |
$167.8 |
10.1% |
|
Inventory |
$150.7 |
$128.6 |
17.2% |
|
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Accounts Payable* |
$186.8 |
$203.1 |
(8%) |
|
Long-Term Debt |
No Data |
$20.6 |
No Data |
Learn the ways of the balance sheet.
Cash Flow Highlights
|
Q3 2006 |
Q3 2005 |
Change | |
|---|---|---|---|
|
Cash From Ops. |
$205.4 |
$84.4 |
143.4% |
|
Capital Expenditures |
$11.3 |
$15.9 |
(28.9%) |
|
Free Cash Flow |
$194.1 |
$68.5 |
183.4% |
Find out why Fools always follow the money.
Related Companies:
- Mylan Laboratories (NYSE:MYL)
- Watson Pharmaceuticals (NYSE:WPI)
- Par Pharmaceutical (NYSE:PRX)
- Caraco Pharmaceutical Laborato (AMEX:CPD)
Related Foolishness:
How do you think Barr will do in the next few weeks? How about the next few years? Join CAPS, the Fool's new community-intelligence stock-rating service, and tell more than 12,000 fellow investors how you feel.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
